Abstract:The gp41 transmembrane domain of the envelope glycoprotein of the human immunodeficiency virus (HIV) modulates the conformation of the viral envelope spike. During the HIV fusion process, C-terminal heptad repeat (CHR, C34) wrap antiparallel to the N-terminal heptad repeat (NHR, N36) helices to form a stable six-helix bundle (6-HB) core structure, which brings the viral and cell membranes into close proximity for fusion. Therefore, inhibiting the formation of 6-HB is considered to be a key activity of an effective HIV-1 fusion inhibitor. The level of arachidonic acid (AA) is increased in HIV infected patients. Our study provides a new insight into the functional role of AA during the formation of HIV-1 gp41 6-HB. Native polyacrylamide gel electrophoresis (N-PAGE), enzyme-linked-immunosorbent serologic assay (ELISA) and circular dichroism (CD) spectroscopy were used to investigate the inhibition of AA for the formation of 6-HB. Molecular docking technique was adopted to explore the underlying mechanism. HIV-1 JR-FL (R5 strain) Envelope was adopted to determine the inhibition effect of AA. AA is shown to interfere with the formation of α-helical complexes of N36 and C34 by N-PAGE, ELISA and CD spectroscopy. The isotherm titration microcalorimetry (ITC) results indicate there is a single class of binding site on N36. ΔH and ΔS are -12.43 kJ mol-1 and 70.07 J mol-1 K-1, respectively, indicating hydrophobic interaction and electrostatic forces are the main acting forces. The molecular docking results manifest that AA interacts with the hydrophobic residues (Trp-571, Leu-568, Val-570 and Leu-576) and ionic interactions occur between Arg-579 and the -COOH of AA. The inhibitory activity of AA on HIV-1 JR-FL is quantified by 50% effective concentration (EC50) and 90% effective concentration (EC90), which are 31.42 ± 1.08 and 133.47 ± 18.10 μg mL-1, respectively. All the results indicate that AA is able to inhibit the formation of 6-HB but cannot disrupt the preformed 6-HB. Therefore, AA is a potential inhibitor for the viral fusion/entry.

P20A Inhibits HIV-1 Fusion Through Its Electrostatic Interaction with the Distal Region of the Gp41 Fusion Core.

HIV-1 Variants with a Single-Point Mutation in the Gp41 Pocket Region Exhibiting Different Susceptibility to HIV Fusion Inhibitors with Pocket- or Membrane-Binding Domain.

ST103 HIV-1 Variants with Mutations in the Gp41 Pocket Region Are Resistant to HIV Fusion Inhibitors with Pocket-Binding Domain, but Sensitive to T20

USP49 Potently Stabilizes APOBEC3G Protein by Removing Ubiquitin and Inhibits HIV-1 Replication

Identification of a Gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein As a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor

P848 Revisiting Enfuvirtide’s Mechanism and Designing Its Analog with Improved Activity by Targeting Triple Sites in Gp41

Mutations of Gln64 in the HIV-1 Gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the Gp41 Pocket

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.

Structural and Functional Characterization of HIV-1 Cell Fusion Inhibitor T20.

Adding An Artificial Tailanchor To A Peptide-Based Hiv-1 Fusion Inhibitor For Improvement Of Its Potency And Resistance Profile

Hydrophobic Mutations In Buried Polar Residues Enhance Hiv-1 Gp41 N-Terminal Heptad Repeat-C-Terminal Heptad Repeat Interactions And C-Peptides' Anti-Hiv Activity

HIV Gp41 C-terminal Heptad Repeat Contains Multifunctional Domains: RELATION TO MECHANISMS OF ACTION OF ANTI-HIV PEPTIDES

Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile

Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket

Investigation of the inhibition effect of arachidonic acid on the core structure of the HIV-1 gp41

The Glu143 Residue Might Play a Significant Role in T20 Peptide Binding to HIV-1 Receptor gp41: An In Silico Study

Potent Hiv Fusion Inhibitors Against Enfuvirtide-Resistant Hiv-1 Strains

Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect Against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains

Interactions Between Different Generation HIV‐1 Fusion Inhibitors and the Putative Mechanism Underlying the Synergistic Anti‐hiv‐1 Effect Resulting from Their Combination

Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.